推荐产品
应用
使用经验证可用于ELISA &WB的兔抗人IgG抗体，HRP偶联物检测人IgG。
法律信息
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 3
Bibek Parajuli et al.
Biochemistry, 55(44), 6100-6114 (2016-10-13)
We recently reported the discovery of a recombinant chimera, denoted DAVEI (dual-acting virucidal entry inhibitor), which is able to selectively cause specific and potent lytic inactivation of both pseudotyped and fully infectious human immunodeficiency virus (HIV-1) virions. The chimera is
Antigen discovery by bioinformatics analysis and peptide microarray for the diagnosis of cystic echinococcosis.
Batisti Biffignandi, et al.
PLoS Neglected Tropical Diseases, 17, e0011210-e0011210 (2023)
Bibek Parajuli et al.
The Biochemical journal, 475(5), 931-957 (2018-01-19)
We previously reported a first-generation recombinant DAVEI construct, a dual action virus entry inhibitor composed of cyanovirin-N (CVN) fused to a membrane proximal external region or its derivative peptide Trp3. DAVEI exhibits potent and irreversible inactivation of HIV-1 (human immunodeficiency
Kasopefoluwa Y Oguntuyo et al.
medRxiv : the preprint server for health sciences (2020-08-21)
The global COVID-19 pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the SARS-CoV-2 spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires extensive
Kasopefoluwa Y Oguntuyo et al.
mBio, 12(1) (2021-02-18)
The global coronavirus disease 2019 (COVID-19) pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent-phase plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门